Latest Innovation News

Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.

Helia Group reveals ING Bank Australia will not renew its Lenders Mortgage Insurance contract beyond June 2026, prompting a strategic business review amid evolving market dynamics.

Talius Group has secured its first purchase order from Wesco Anixter and signed a global expansion agreement, while subscription numbers near 49,000 amid ongoing pilot programs and regulatory shifts.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

Peak Minerals reports a significant expansion of heavy mineral zones at its Minta Rutile Project in Cameroon, with consistent rutile mineralisation confirmed across a vast 1,500 square kilometres. The company advances toward a maiden Mineral Resource Estimate in 2026, supported by promising alluvial and residual assay results.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Objective Corporation has agreed to acquire Isovist, a leading e-planning software provider for local governments in Australia and New Zealand, enhancing its Planning and Building sector capabilities.

Orpheus Uranium has launched a targeted exploration program at its Mt Douglas Project in the Northern Territory, supported by a government co-funding grant and approved permits enabling advanced drilling activities.

Wide Open Agriculture Limited reminds shareholders of the imminent closing of its Securities Purchase Plan, offering shares at a discounted price with free options, while gearing up for an investor webinar to discuss company progress.

archTIS Limited has secured A$7.5 million through a discounted share placement to fund expansion in the U.S. defence sector, deepen strategic partnerships, and accelerate product innovation focused on secure data collaboration.

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.